Abstracts tagged "scleroderma and skin fibrosis"

Abstract Number: 129 • 2018 ACR/ARHP Annual Meeting
Rnaseq Analysis of Human Skin in Organ Culture Identifies Collagen 22A1 As a TGF-β Early Response Gene
Tomoya Watanabe¹, Logan Mlakar², Jonathan Heywood³, Willian da Silveira⁴, Gary Hardiman⁵ and Carol A. Feghali-Bostwick⁶, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, ³Rheumataology, Medical University of South Carolina, Chareston, SC, ⁴Center for Genomic Medicine, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁶Department of Medicine, Medical University of South Carolina, Division of Rheumatology and Immunology, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a complex multi-system autoimmune disease characterized by immune dysregulation, vasculopathy, and organ fibrosis. Skin fibrosis causes high morbidity and impaired…
Abstract Number: 1728 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Claudia Macaubas¹, Emily Mirizio², Kaila Schollaert-Fitch³, Elizabeth D. Mellins⁴ and Kathryn S. Torok³, ¹Department of Pediatrics, Program in Immunology, Stanford University Med Ctr, Stanford, CA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA
Background/Purpose: Localized scleroderma (LS) has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The understanding of the pathophysiology…
Abstract Number: 801 • 2016 ACR/ARHP Annual Meeting
Multi-Tissue Gene Expression Pathway Analysis of Emerging Therapeutics in a TGFβ Dependent Mouse Model of Systemic Sclerosis
Emma C. Derrett-Smith^1,2, Shiwen Xu³, Rachel K. Hoyles⁴ and Christopher Denton⁵, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ²Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ⁴Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: We have previously investigated the interplay between TGFβ, BMP, VEGF and endothelin in SSc using the TβRIIΔk-fib strain, a transgenic mouse model in…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 1891 • 2015 ACR/ARHP Annual Meeting
Parameters That Predict Worsening of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis
Masataka Kuwana¹, Minoru Hasegawa², Yucihiro Shirai¹, Osamu Ishikawa³, Hirahito Endo⁴, Fumihide Ogawa⁵, Daisuke Goto⁶, Shinichi Sato⁷, Hironobu Ihn⁸, Yasushi Kawaguchi⁹ and Kazuhiko Takehara¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, ³Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan, ⁴Department of Rheumatology, Jusendo General Hospital, Koriyama, Japan, ⁵Department of Dermatology, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan, ⁶Division of Clinical Immunology, Doctoral Program in Clinical Sciences, University of Tsukuba, Graduate School of Comprehensive Human Sciences, Tsukuba, Japan, ⁷Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Japan
Background/Purpose: Skin thickness is a hallmark of systemic sclerosis (SSc), and its progression is associated with poor prognosis. The modified Rodnan total skin thickness score…
Abstract Number: 3013 • 2015 ACR/ARHP Annual Meeting
Adipose Loss of Co-Repressor Ncor Attenuates Bleomycin-Induced Skin Fibrosis By Enhancing PPAR-Gamma Signaling
Benjamin Korman¹, Roberta Goncalves Marangoni¹, Warren Tourtellotte² and John Varga³, ¹Division of Rheumatology, Northwestern University, Chicago, IL, ²Department of Pathology, Ward, Northwestern University, Chicago, IL, ³Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
Background/Purpose: The adipogenesis master regulator PPAR-gamma (PPARg) is regulated by repressors such as NCoR. Systemic sclerosis (SSc) is associated with impaired PPARg expression and function…
Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Katia Urso¹, Kelly Tsang², Robert Lafyatis³ and Antonios O. Aliprantis², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
Abstract Number: 965 • 2014 ACR/ARHP Annual Meeting
Blockade of TLR4 Signaling By TAK242 Ameliorates Experimental Organ Fibrosis
Swati Bhattacharyya¹, Wenxia Wang¹, Zenshiro Tamaki², Yasuhiro Tsukimi³, Masashi Yamasaki³ and John Varga⁴, ¹Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ³Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Our recent studies implicate innate immune signaling through Toll like receptor 4 (TLR4) in scleroderma pathogenesis. Aberrant production and accumulation of the endogenous TLR4…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].